Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX

Vaccination; Infection Clinical Trial

— CHRONOVAX  

Official title:

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06088563
• Other study ID #: 23-PP-09
• Status: Recruiting
• Phase: N/A
• Start date: October 26, 2023
• Est. completion date: October 26, 2024

Study information

• Verified date: January 2024
• Source: Centre Hospitalier Universitaire de Nice
• Contact: GOSSET Clément, MD
• Phone: 492038632
• Email: gosset.c[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Immune response to influenza vaccine in kidney transplant patients

Description:

Seasonal influenza vaccination is recommended for kidney transplant patients, as influenza is responsible for significant morbidity and mortality in this immunocompromised population. Nevertheless, injection of influenza vaccine induces a protective immune response in only 20% to 40% of patients. Today, there are no recommendations regarding the injection time of influenza vaccine in the general population or in immunocompromised patients. In this context, recent studies conducted in healthy subjects have shown that the time of vaccination can have an impact on vaccine efficacy. This is the case for BCG, influenza, COVID-19. On this basis, we formulate the main hypothesis that the administration of influenza vaccine to kidney transplant patients would be more effective when carried out in the morning than in the evening.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: October 26, 2024
• Est. primary completion date: October 26, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Renal transplant patient;
• Follow-up at Nice University Hospital;
• Age > 18 years;
• Indication for influenza vaccination
• Free and informed consent;
• Immunosuppressive treatment including anti-calcineurin and/or Mycophenolate Mofetil (with or without corticoids).

Exclusion Criteria:

• Known hypersensitivity to influenza vaccine or egg proteins;
• Influenza vaccination for the 2023-2024 season already performed;
• Current infection;
• Current acute medical condition;
• Treatment of rejection within the previous 3 months;
• Immunosuppressive therapy including CTLA4 agonist, mTOR inhibitor, complement inhibitor, anti-CD19;
• Polyvalent immunoglobulin infusion within the preceding 3 months;
• Vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French);
• Subjects not affiliated to the Social Security system.

Related Conditions & MeSH terms

• Influenza, Human
• Vaccination; Infection

Intervention

Other:
• Vaccine injection
Injection of the vaccine in renal transplant patients.

Locations

Country	Name	City	State
France	CHU Nice - Hôpital Pasteur 2	Nice	Alpes-Maritimes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of antibody titer (seroconversion) 4 weeks after inactivated influenza vaccine injection in each arm.	Seroconversion will be defined as an increase in antibody titer of at least 4-fold (=4) over pre-vaccination titer AND an antibody titer = 1:40 (seroprotection) four weeks post-vaccination, for at least one of the three vaccine antigens.	7 months
Secondary	Number of seasonal influenza virus infections in each arm.	Comparing the number of seasonal influenza virus infections in kidney transplant patients between a group of patients vaccinated in the morning and a group vaccinated in the evening.; The occurrence of influenza, as confirmed by a PCR test, will be noted in the follow-up consultation.	8 months
Secondary	Comparison the evolution of antibody titres reacting in each arm.	In kidney transplant patients, compare the evolution of antibody titres reacting with vaccine antigens 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.; The titer of antibodies reacting with vaccine antigens is measured by ELISA ;	7 months
Secondary	Evolution of the number of memory B cells in each arm.	To compare in kidney transplant patients the evolution of the number of memory B cells reacting with vaccine antigens 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.; The number of memory B cells reacting with vaccine antigens will be measured by ELISPOT ;	7 months
Secondary	Evolution of the number of CD4+ T cells in each arm.	Comparing the evolution of CD4+ T cells reacting with vaccine antigens in kidney transplant patients 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.; The number of CD4+ T cells reacting with vaccine antigens will be measured by in vitro proliferation assay;	7 months
Secondary	Evolution of the number of CD8+ T cells in each arm.	Comparing the evolution of CD8+ T cells reacting with vaccine antigens in kidney transplant patients 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.; The number of CD8+ T cells reacting with vaccine antigens will be measured by in vitro proliferation assay;	7 months